Dr. Lal PathLabs Limited
NSE: LALPATHLABMarket Closed • NSE
Day range
52 week range
Dr. Lal PathLabs Limited closed at INR1859.90 (-1.34%) on volume 0.83x its 20-day average, trading 8.77% below its 52-week high.
2026-Q2
Q2 FY2026 Financial Results
PAT moved +29.1% QoQ
2026-07-30
DIVIDEND Announced
Interim Dividend - Rs 5 Per Share
2026-06-25
DIVIDEND Announced
Dividend - Rs 4 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Low Debt Profile: Debt-to-Equity is comfortable at 0.08x
High Cash Flow Conversion: CFO/PAT averaged 1.17x over last 3 years
Risks
Stretched Valuation: Trading at a high P/E multiple of 57.4x
Bull case
Market Leadership: Established operational scale in Diagnostics & Research.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 30 Jul 2026 | Dividend | ₹5.00 / share | — | 30 Jul 2026 |
| 26 Jun 2026 | Dividend | ₹4.00 / share | — | 25 Jun 2026 |
| 05 Feb 2026 | Dividend | ₹3.50 / share | — | 05 Feb 2026 |
| 19 Dec 2025 | Bonus issue | 1:1 bonus ratio | — | 19 Dec 2025 |
| 07 Nov 2025 | Dividend | ₹7.00 / share | — | 07 Nov 2025 |
| 06 Aug 2025 | Dividend | ₹6.00 / share | — | 06 Aug 2025 |
| 06 Jun 2025 | Dividend | ₹6.00 / share | — | 06 Jun 2025 |
| 05 Feb 2025 | Dividend | ₹6.00 / share | — | 05 Feb 2025 |
| 05 Nov 2024 | Dividend | ₹6.00 / share | — | 05 Nov 2024 |
| 20 Aug 2024 | Dividend | ₹6.00 / share | — | 20 Aug 2024 |
| 10 Jun 2024 | Dividend | ₹6.00 / share | — | 10 Jun 2024 |
| 13 Feb 2024 | Dividend | ₹12.00 / share | — | 13 Feb 2024 |
| 11 Aug 2023 | Dividend | ₹6.00 / share | — | 11 Aug 2023 |
| 09 Aug 2022 | Dividend | ₹6.00 / share | — | 05 Aug 2022 |
| 23 Jun 2022 | Dividend | ₹6.00 / share | — | 22 Jun 2022 |
| 22 Aug 2021 | Dividend | ₹6.00 / share | — | 18 Aug 2021 |
| 22 Jul 2021 | Dividend | ₹8.00 / share | — | 20 Jul 2021 |
| 10 Feb 2021 | Dividend | ₹6.00 / share | — | 09 Feb 2021 |
| 19 Nov 2020 | Dividend | ₹6.00 / share | — | 18 Nov 2020 |
| 06 Mar 2020 | Dividend | ₹6.00 / share | — | 05 Mar 2020 |
| 21 Nov 2019 | Dividend | ₹6.00 / share | — | 20 Nov 2019 |
| — | Dividend | ₹3.50 / share | — | 02 Aug 2019 |
| 20 Nov 2018 | Dividend | ₹2.50 / share | — | 19 Nov 2018 |
| — | Dividend | ₹3.00 / share | — | 03 Aug 2018 |
| 21 Nov 2017 | Dividend | ₹1.50 / share | — | 20 Nov 2017 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Dr. Lal PathLabs Limited operates laboratories for carrying out pathological investigations in India and internationally. The company provides pathological investigations of various branches of bio-chemistry, hematology, histopathology, microbiology, electrophoresis, immuno-chemistry, immunology, virology, cytology, and other pathological and radiological investigations. It also offers phlebotomist training programs. The company was founded in 1949 and is based in Gurugram, India.
IndiaHealthcare
Is Dr. Lal PathLabs Limited Shariah compliant?
Dr. Lal PathLabs Limited is currently screened as Non-Compliant (Financial Ratios) under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (783%) exceeds AAOIFI threshold (≤ 33%).
What is Dr. Lal PathLabs Limited's current valuation relative to peers?
Dr. Lal PathLabs Limited trades at a P/E of 57.4x compared to the sector median of 37x, and a Price-to-Book of 12.4x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.08x. Interest coverage is comfortable.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at 6.5% while net profit growth averaged 16.1%.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.